Metformin Hydrochloride (CAS NO : 1115-70-4)

The global Metformin Hydrochloride (CAS No: 1115-70-4) market is undergoing a significant transition toward high-efficiency formulations, with extended-release (ER) variants now constituting over 40% of new product developments to improve patient compliance and mitigate the gastrointestinal side effects reported by nearly 15% of the patient population. As the definitive first-line therapy for type 2 diabetes management, Metformin HCl remains the primary anti-hyperglycemic agent in approximately 77% of global prescriptions, driving the market toward a projected valuation of USD 34.33 billion by 2033. Current industry dynamics highlight a critical shift in the manufacturing landscape, where Indian pharmaceutical manufacturers now control over 35% of the global supply, leveraging high-volume generic production to meet the soaring demand from the Asia-Pacific region, which currently accounts for 52% of global consumption. Furthermore, the market is expanding beyond traditional diabetic indications, with increasing clinical adoption in the management of Polycystic Ovary Syndrome (PCOS) and weight management therapies, necessitating rigorous API quality standards to support diverse therapeutic applications. We are an established Metformin Hydrochloride API supplier with >= 99% purity globally for semi-finished formulators, providing comprehensive analytical (HPLC/NMR/MS) and supporting Metformin Hydrochloride COA/TDS/SDS region-specific regulatory support, reliable lead times, and worldwide supply chain capabilities.